Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development
This article was originally published in RPM Report
Executive Summary
A stakeholder project on obesity treatment outcomes will complete its work this summer, setting the stage for FDA to rethink efficacy endpoints for weight loss drug development. The closed-door project is happening in parallel with public advisory committee discussions on pending applications and safety standards. One impact will be to shape more formal patient-centered drug development activities in years to come.
You may also be interested in...
“Scoring” Savings From Obesity Drugs: CBO Points To Gap Between Categories In Rx Labels And Economic Impact
Proposals to expand Medicare coverage to include obesity therapies are unlikely to be treated as cost-effective by CBO without significant new research on the long term impact of relatively modest changes in BMI. Advocates for coverage may need to focus on other arguments instead.
“Scoring” Savings From Obesity Drugs: CBO Points To Gap Between Categories In Rx Labels And Economic Impact
Proposals to expand Medicare coverage to include obesity therapies are unlikely to be treated as cost-effective by the Congressional Budget Office without significant new research on the long term impact of relatively modest changes in BMI. Advocates for coverage may need to focus on other arguments instead.
Obesity Therapy Gap Or Regulatory Gap? REMS Not The Answer For Belviq Or GW Group
A common theme in FDA’s review of three different weight loss drugs has been discussion of whether a Risk Evaluation & Mitigation Strategy program can help assure appropriate use of the therapies. FDA clearly thinks the answer is “no.” But that doesn’t end the discussion of what tools can be used to help curb off-label use.